Drug intelligence / Profile preview

LPCN 2203

Development stage: Unknown
Lead developer: Lipocine
Modality: Small Molecules
Administration: Oral

Overview

LPCN 2203 is an orally administered small molecule drug under development by Lipocine for the treatment of essential tremor. It acts as a gamma-aminobutyric acid A (GABAA) receptor modulator, aiming to manage symptoms of essential tremor by targeting GABAergic neurotransmission in the central nervous system. The drug utilizes Lipocine's proprietary Lip'ral technology for oral delivery and is currently in Phase 1 clinical trials for this indication[1][2][5].

Targets

GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on LPCN 2203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LPCN 2203.

Explore the full profile